Arbutus Biopharma
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ABUS and other ETFs, options, and stocks.About ABUS
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV).
CEOLindsay Androski
CEOLindsay Androski
Employees44
Employees44
HeadquartersWarminster, Pennsylvania
HeadquartersWarminster, Pennsylvania
Founded2005
Founded2005
Employees44
Employees44
ABUS Key Statistics
Market cap597.56M
Market cap597.56M
Price-Earnings ratio-7.77
Price-Earnings ratio-7.77
Dividend yield—
Dividend yield—
Average volume773.68K
Average volume773.68K
High today$3.19
High today$3.19
Low today$3.08
Low today$3.08
Open price$3.19
Open price$3.19
Volume886.74K
Volume886.74K
52 Week high$4.73
52 Week high$4.73
52 Week low$2.71
52 Week low$2.71
ABUS News
TipRanks 8h
Arbutus Biopharma’s AB-101 Study: A Potential Game-Changer in Chronic Hepatitis B TreatmentArbutus Biopharma ((ABUS)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off...
People also own
Based on the portfolios of people who own ABUS. This list is generated using Robinhood data, and it’s not a recommendation.